San Francisco, CANCT06949800Now EnrollingIRB Ready

HSIL, High Grade Squamous Intraepithelial Lesion Clinical Trial in San Francisco, CA

Access cutting-edge hsil, high grade squamous intraepithelial lesion treatment through this phase 2 clinical trial at a research site in San Francisco. Study-provided care at no cost to qualified participants.

Sponsored by University of California, San Francisco

Quick Self-Assessment

See if you qualify for this San Francisco location

Preparing your pre-screening questions…

Expert Care in San Francisco

Access hsil, high grade squamous intraepithelial lesion specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related hsil, high grade squamous intraepithelial lesion treatment provided free

Apply for This San Francisco Location

Check if you qualify for this hsil, high grade squamous intraepithelial lesion clinical trial in San Francisco, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to San Francisco

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit San Francisco site if eligible
  4. 4Begin participation

About This HSIL, High Grade Squamous Intraepithelial Lesion Study in San Francisco

This study is focused on treatment of anal high-grade squamous intraepithelial lesions (HSIL) in persons with HIV (PWH), with the ultimate goal of applying the approach toward prevention of anal cancer in this population

Sponsor: University of California, San Francisco

Who Can Participate

Inclusion Criteria

Signed informed consent
Participant in ULACNet-101 or participant screened specifically for ULACNet-102.
Biopsy-proven anal HSIL (men or women) shown as part of participation in the ULACNet-101 study or at a screening visit for ULACNet-102.
At least one focus of anal HSIL must be large enough to be monitored for response, i.e.,not completely removed after the screening biopsy.
Total volume of HSIL is less than 50% of the anal canal or perianal region.
Must be actively on treatment with effective antiretroviral therapy (ART) regimen for at least three months preceding enrollment (Visit 1, Day 1) in ULACNet-101 or at screening for ULACNet-102.
HIV RNA \<200 copies/ml at baseline.
Cluster of differentiation 4 (CD4) nadir above 200 cells per microliter (uL)
Eastern Cooperative Oncology Group (ECOG) performance status \<=1 (Karnofsky \>= 70%).
Participants must meet the following laboratory parameters within 3 months before enrollment:
Leukocytes: ≥3,000/mm\^3.
Absolute neutrophil count: ≥1,500/mm\^3.
Platelets: ≥100,000/mm\^3.
Elevation of aspartate aminotransferase (AST), alanine aminotransferase (ALT), or bilirubin \<2 times the upper limit of normal.
Not pregnant or breast feeding and one of the following:
Of non-childbearing potential (i.e. persons aged 60 years or older or who have had a hysterectomy or tubal ligation or are postmenopausal, as defined by no menses for at least 12 months and without an alternative medical cause).
Persons aged less than 60 years of childbearing potential and agree to practice highly effective contraception from initiation of taking EXE-346 or placebo through 14 days after taking the last dose of EXE-346 or placebo. Highly effective methods of contraception include one or more of the following: i.Male partner who is sterile (medically effective vasectomy) prior to the female participant's entry into the study and is the sole sexual partner for the female participant. ii.Hormonal (oral, intravaginal, transdermal, implantable or injectable); Progestogen-only hormonal contraceptives without inhibition of ovulation are not considered to be highly effective. iii. An intrauterine hormone-releasing system. iv. An intrauterine device. v. Bilateral tubal occlusion or removal. vi. Sexual abstinence, only if the participant refrains from heterosexual intercourse from initiation taking EXE-346 or placebo through 14 days after taking the last dose of EXE-346 or placebo and it is the usual lifestyle of the participant.

Exclusion Criteria

History of any anogenital cancer.
Presence of untreated cervical HSIL or cervical cancer.
Anal HSIL on clinical examination or biopsy that clinicians are concerned for cancer.
Receipt of chemotherapy, radiotherapy or immunosuppressive medication in three months preceding enrollment in ULACNet-101 or at the screening visit for ULACNet-102.
Immunosuppression as a result of underlying illness or treatment including:
Use of high dose corticosteroids (\>10 mg/day prednisone or equivalent) for \>=7 days (inhaled, otic, topical and ophthalmic corticosteroids are permitted).
Primary immune deficiency disease.
Use of synthetic or biologic disease-modifying anti-rheumatic drugs.
History of bone marrow or solid organ transplant.
History of any other clinically significant autoimmune or immunosuppressive disease.
Participant initiated a new treatment with antibiotics within the 2 weeks prior to screening or plans to start antibiotic therapy during the study period.
Participant is taking NSAIDs as a long-term treatment (ie, consistent use for at least 4 days/week each month). Acute use of NSAIDs is allowed.
Participant has known hypersensitivity to EXE-346 or any product components.
Current known infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Warts so extensive that they preclude the clinician from determining the extent and location of HSIL.
Sustained, manually confirmed, sitting systolic blood pressure \>150 mm Hg or \<90 mm Hg or a diastolic blood pressure \>95 mm Hg as measured by 3 readings taken 15 minutes apart at screening or Visit 1.
History of significant thrombocytopenia, history of thrombosis with thrombocytopenia (TTS) syndrome or heparin-induced thrombocytopenia.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, cardiac arrhythmia, or psychiatric illness/social situations that, in the opinion of the investigator, would limit compliance with study requirements.
Participant has participated in any clinical study of an approved or unapproved investigational medicinal product within the 30 days prior to screening.
Any other finding that, in the opinion of the Investigator deems the participant unsuitable for the study

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in San Francisco?

Yes, this clinical trial (NCT06949800) has an active research site in San Francisco, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

HSIL, High Grade Squamous Intraepithelial Lesion Treatment Options in San Francisco, CA

If you're searching for hsil, high grade squamous intraepithelial lesion treatment options in San Francisco, CA, this clinical trial (NCT06949800) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our San Francisco research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced hsil, high grade squamous intraepithelial lesion specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all hsil, high grade squamous intraepithelial lesion clinical trials near you to find additional studies recruiting in your area.

More Alzheimers Disease Trials in San Francisco, CA

See all alzheimers disease clinical trials recruiting in San Francisco — not just this study.

Browse Alzheimers Disease Trials in San Francisco →

Browse More Trials by Condition

Alzheimers Disease TrialsRheumatoid Arthritis TrialsAtopic Dermatitis TrialsHidradenitis Suppurativa TrialsAll Conditions →

Ready to Join in San Francisco?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · San Francisco, CA